Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction
Open Access
- 1 July 2010
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 150 (2) , 209-217
Abstract
Summary: Pathogen reduction (PR) of platelet products increases costs and available clinical studies are equivocal with respect to clinical and haemostatic effectiveness. We conducted a multicentre, open‐label, randomized, non‐inferiority trial comparing the clinical effectiveness of buffy‐coat derived leucoreduced platelet concentrates (PC) stored for up to 7 d in plasma with platelets stored in platelet additive solution III (PASIII) without and with treatment with amotosalen‐HCl/ultraviolet‐A (UVA) photochemical pathogen reduction (PR‐PASIII). Primary endpoint of the study was 1‐h corrected count increment (CCI). Secondary endpoints were 24‐h CCI, bleeding, transfusion requirement of red cells and PC, platelet transfusion interval and adverse transfusion reactions. Compared to plasma‐PC, in the intention to treat analysis of 278 evaluable patients the mean difference for the 1‐h CCI of PR‐PASIII‐PC and PASIII‐PC was −31% (P < 0·0001) and −9% (P = n.s.), respectively. Twenty‐seven patients (32%) had bleeding events in the PR‐PASIII arm, as compared to 19 (19%) in the plasma arm and 14 (15%) in the PASIII arm (P = 0·034). Despite the potential advantages of pathogen (and leucocyte) inactivation of amotosalen‐HCl/UVA‐treated platelet products, their clinical efficacy is inferior to platelets stored in plasma, warranting a critical reappraisal of employing this technique for clinical use.Keywords
This publication has 36 references indexed in Scilit:
- Dose of Prophylactic Platelet Transfusions and Prevention of HemorrhageNew England Journal of Medicine, 2010
- Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopeniaTransfusion, 2006
- Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trialTransfusion, 2006
- Transfusion of 7‐day‐old amotosalen photochemically treated buffy‐coat platelets to patients with thrombocytopenia: a pilot studyTransfusion, 2006
- Platelet ADP response deteriorates in synthetic storage mediaTransfusion, 2005
- Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT TrialBlood, 2004
- Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis plateletsVox Sanguinis, 2004
- Transfusion‐transmitted bacterial infectionin the United States, 1998 through 2000Transfusion, 2001
- Pathogen inactivation of labile blood productsTransfusion Medicine, 2001
- Functional Characteristics of S‐59 Photochemically Treated Platelet Concentrates Derived from Buffy CoatsVox Sanguinis, 2000